AbbVie (ABBV) said that a subcutaneous version of Skyrizi (risankizumab) for Crohn’s disease met key goals in a phase 3 trial.
Patients in the AFFIRM study were given either Skyrizi SC or placebo. Those treated with Skyrizi SC induction saw Crohn’s Disease Activity Index clinical remission of 55% vs. 30% with placebo at week 12, and endoscopic response of 44% vs. 14%.
Also, of patients who had a clinical response after 12 weeks of risankizumab SC treatment followed by 12 weeks of maintenance, 67% saw CDAI clinical remission at week 24, and 57% achieved endoscopic response.
